Compare EBS & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBS | ALTI |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | N/A | 490 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.1M | 407.2M |
| IPO Year | 2006 | 2021 |
| Metric | EBS | ALTI |
|---|---|---|
| Price | $8.00 | $3.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 638.8K | 141.1K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.83 | 41.11 |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $742,900,000.00 | $254,956,000.00 |
| Revenue This Year | $1.29 | $18.06 |
| Revenue Next Year | N/A | $10.71 |
| P/E Ratio | $8.66 | ★ N/A |
| Revenue Growth | N/A | ★ 23.21 |
| 52 Week Low | $4.71 | $2.96 |
| 52 Week High | $14.06 | $5.45 |
| Indicator | EBS | ALTI |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 49.63 |
| Support Level | $7.73 | $3.73 |
| Resistance Level | $8.54 | $3.82 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 21.09 | 50.00 |
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.